Reaction

Sinus Node Dysfunction reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,807 reports · 56 co-occurring drugs

As of the last recalculation, Sinus Node Dysfunction appears in 1,807 FAERS reports alongside 56 co-occurring drug terms. The strongest observed disproportionality signal is AMIODARONE HYDROCHLORIDE (PRR 33.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Amiodarone Hydrochloride	32	33.5	33.6
Lacosamide	62	19.8	19.9
Sofosbuvir	33	19.6	19.6
Donepezil Hydrochloride	59	19.1	19.1
Lithium	34	15.8	15.8
Lithium Bromatum	34	15.8	15.8
Nebivolol	21	15.4	15.4
Telmisartan	23	15.0	15.0
Eplerenone	16	14.5	14.5
Bisoprolol Fumarate	154	14.2	14.2
Sotalol Hydrochloride	19	13.3	13.3
Lithium Carbonate	19	13.0	13.0
Granisetron Hydrochloride	11	12.2	12.2
Torsemide	34	12.0	12.0
Tafamidis	11	10.8	10.8
Ticagrelor	29	10.6	10.6
Pitavastatin Calcium	9	10.2	10.2
Vibegron	7	10.1	10.1
Digoxin	60	9.9	9.9
Dofetilide	9	9.9	9.9
Atropine	7	9.8	9.8
Ferrous Sulfate	40	9.4	9.4
Spironolactone	107	9.3	9.3
Indapamide	14	9.1	9.1
Methimazole	6	8.8	8.8
Daptomycin	7	8.8	8.8
Apixaban	49	8.6	8.6
Levetiracetam In Sodium Chloride	56	8.6	8.6
Levetiracetam Oral	56	8.6	8.6
Levetiracetam Injection	56	8.6	8.6
Sevoflurane	6	8.3	8.3
Rasagiline Mesylate	8	8.3	8.3
Tolvaptan	10	8.0	8.0
Febuxostat Tablets 40 Mg	7	8.0	8.0
Febuxostat Tablets 80 Mg	7	8.0	8.0
Nebivolol Hydrochloride	23	7.9	7.9
Remdesivir	9	7.8	7.8
Dapagliflozin	20	7.4	7.4
Daratumumab	24	7.0	7.0
Rocuronium Bromide	7	6.9	6.9
Granisetron	6	6.6	6.6
Canakinumab	6	6.4	6.4
Brimonidine Tartrate	9	5.8	5.8
Brexpiprazole	8	5.6	5.6
Ibrutinib	37	5.4	5.4
Dabigatran Etexilate	33	5.0	5.0
Azacitidine For	7	4.4	4.4
Inclisiran	3	4.3	4.3
Dabigatran Etexilate Mesylate	23	3.7	3.7
Crizotinib	4	3.6	3.6
Romosozumab-Aqqg	4	3.4	3.4
Ixazomib	8	3.2	3.2
Methoxy Polyethylene Glycol-Epoetin Beta	3	3.1	3.1
Paliperidone Palmitate	8	2.9	2.9
Sacubitril And Valsartan	27	2.7	2.7
Nirmatrelvir And Ritonavir	9	1.9	1.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.